Genetic Hemochromatosis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Genetic hemochromatosis (also called hereditary hemochromatosis or HH) is a lifelong, autosomal‑dominant disorder that causes the body to absorb too much dietary iron. The excess iron is stored in organs such as the liver, heart, pancreas, joints, and skin, eventually leading to tissue damage if left untreated.

‑ **Who it affects** – The condition is most common in people of Northern European descent, especially those of Celtic (Irish, Scottish, Welsh) or Scandinavian ancestry. Men typically develop clinical disease earlier than women because menstruation and pregnancy provide a natural iron‑loss pathway.

‑ **Prevalence** – Approximately 1 in 200–250 people (0.4–0.5 %) in the United States and Europe carry two copies of the most common pathogenic variant (C282Y) in the HFE gene, making them “genetically at‑risk.” However, only about 10 % of these individuals will develop significant organ damage, highlighting the role of additional genetic and environmental modifiers.<sup>1</sup>

Symptoms

Symptoms often appear in mid‑life (40‑60 years for men, 50‑70 years for women) and develop gradually. Many patients are asymptomatic at diagnosis during routine screening.

• Fatigue & weakness – Persistent low energy is the most frequently reported complaint.
• Joint pain – Often involves the second and third metacarpophalangeal (MCP) joints, knees, hips, and ankles.
• Abdominal pain – Related to liver enlargement (hepatomegaly) or early cirrhosis.
• Skin hyperpigmentation – A bronze or grayish discoloration, especially on the face and hands.
• Sexual dysfunction – Decreased libido, erectile dysfunction in men, or menstrual irregularities in women.
• Cardiac symptoms – Palpitations, shortness of breath, or heart failure due to iron‑induced cardiomyopathy.
• Diabetes mellitus – “Bronze diabetes” describes the coexistence of hyperpigmentation and insulin‑dependent diabetes.
• Hepatic manifestations – Elevated liver enzymes, hepatomegaly, fibrosis, or cirrhosis; occasional hepatic steatosis.
• Hormonal disturbances – Hypothyroidism, hypogonadism, or adrenal insufficiency.
• Enlarged spleen (splenomegaly) – Less common, usually a sign of advanced disease.

Because symptoms overlap with many other conditions, laboratory testing is essential for a definitive diagnosis.

Causes and Risk Factors

Genetic basis

Hereditary hemochromatosis is most often caused by mutations in the HFE gene, which regulates intestinal iron absorption. The three most clinically relevant variants are:

• C282Y – Homozygosity (two copies) accounts for ~80–90 % of clinically significant cases.
• H63D – Homozygosity or compound heterozygosity (C282Y/H63D) can cause milder disease.
• S65C – Less common, contributes to disease when present with other mutations.

Other genetic contributors

Rare forms involve mutations in HJV (juvenile HH), TFR2, or FTL. These tend to present earlier and may be more severe.

Risk factors that influence expression

• Male sex – Faster iron accumulation because men lack regular blood loss.
• Alcohol consumption – Increases liver injury and accelerates fibrosis.
• Diet high in red meat or iron‑fortified foods – Raises total iron load.
• Co‑existing liver disease (e.g., hepatitis C, non‑alcoholic fatty liver disease).
• Family history of hemochromatosis or related complications.

Diagnosis

Diagnosis follows a stepwise approach that combines clinical suspicion, laboratory testing, imaging, and sometimes genetic analysis.

Screening laboratory tests

1. Serum ferritin – Elevated (>300 ng/mL in men, >200 ng/mL in women) suggests increased iron stores, but can be confounded by inflammation or liver disease.
2. Transferrin saturation (TSAT) – Calculated as (serum iron ÷ total iron‑binding capacity) × 100. A TSAT ≥ 45 % is highly suggestive of HH.
3. Serum iron, total iron‑binding capacity (TIBC), and unsaturated iron‑binding capacity (UIBC) – Provide context for ferritin and TSAT.

Confirmatory testing

• Genetic testing – PCR‑based analysis for C282Y, H63D, and S65C mutations. Homozygosity for C282Y in a patient with elevated ferritin/TSAT essentially confirms the diagnosis.
• Liver MRI (R2* or T2*) – Quantifies hepatic iron concentration non‑invasively, useful for monitoring disease progression.
• Liver biopsy – Reserved for cases where non‑invasive tests are inconclusive or when assessing fibrosis stage.

Diagnostic criteria (simplified)

According to the American Association for the Study of Liver Diseases (AASLD), a diagnosis is established when:

• TSAT ≥ 45 % AND ferritin > 300 ng/mL (men) / > 200 ng/mL (women) AND
• Presence of pathogenic HFE mutation(s) OR direct evidence of iron overload on MRI/biopsy.

Treatment Options

Therapy aims to remove excess iron, prevent organ damage, and address complications.

Phlebotomy (therapeutic venesection)

• First‑line, evidence‑based treatment.
• Standard regimen: 500 mL of blood removed weekly until ferritin falls to 50–100 ng/mL.
• Maintenance phase: Phlebotomy every 2–4 months to keep ferritin in the target range.
• Benefits: Improves liver enzymes, reduces joint pain, reverses early diabetes, and normalizes skin color in many patients.

Chelation therapy

Reserved for patients who cannot tolerate phlebotomy (e.g., severe anemia, cardiac disease, or poor venous access).

• Deferasirox – Oral, taken daily; monitor renal and hepatic function.
• Deferoxamine – Subcutaneous or intravenous infusion; used less frequently due to inconvenience.

Management of complications

• Diabetes – Lifestyle modification, oral hypoglycemics, or insulin as indicated.
• Cirrhosis or liver cancer – Surveillance with ultrasound + AFP every 6 months; consider hepatology referral.
• Cardiomyopathy – Standard heart‑failure therapies; iron removal may improve ejection fraction.
• Arthropathy – NSAIDs, physical therapy, and joint replacement for severe osteoarthritis.

Lifestyle modifications

• Limit dietary iron – Avoid raw shellfish (which contain high heme iron) and limit red meat.
• Avoid vitamin C megadoses (≥ 1 g/day) around meals, as they increase iron absorption.
• Alcohol reduction – No more than 1 drink per day for women, 2 for men.
• Stay hydrated and maintain a balanced diet rich in fruits, vegetables, and whole grains.

Living with Genetic Hemochromatosis

With early detection and regular treatment, most individuals lead normal lives.

Daily management tips

• Keep a phlebotomy schedule – Use a calendar or mobile app to track appointments and ferritin results.
• Monitor labs regularly – Ferritin and TSAT every 3–6 months during the induction phase, then every 6–12 months during maintenance.
• Stay active – Regular moderate exercise supports cardiovascular health and helps control blood glucose.
• Vaccinations – Hepatitis A and B vaccines are recommended, especially if liver disease is present.
• Family screening – First‑degree relatives should be offered HFE genetic testing and iron studies.

Psychosocial considerations

Learning you have a genetic condition can be stressful. Access to counseling, patient support groups (e.g., Hemochromatosis Society of America), and reliable online resources can improve coping and adherence.

Prevention

Because the mutation is inherited, primary prevention is not possible. However, secondary prevention—reducing the risk of organ damage—is achievable:

• Early detection through family screening.
• Adhering to phlebotomy or chelation regimens as prescribed.
• Limiting alcohol intake and avoiding unnecessary iron supplements.
• Managing co‑existing conditions such as hepatitis, obesity, or metabolic syndrome.

Complications

If iron overload is left untreated, excess iron deposits cause irreversible injury.

• Cirrhosis – May progress to liver failure or hepatocellular carcinoma (annual HCC risk ≈ 1–2 % in cirrhotic patients).<sup>2</sup>
• Cardiac disease – Dilated cardiomyopathy, arrhythmias, and congestive heart failure.
• Endocrine dysfunction – Diabetes mellitus, hypogonadism, hypothyroidism, and adrenal insufficiency.
• Arthropathy – Degenerative joint disease, often requiring joint replacement.
• Skin hyperpigmentation – Usually reversible after iron depletion.
• Increased infection risk – Certain bacteria (e.g., Vibrio vulnificus) thrive in iron‑rich environments; avoid raw oysters if iron overload is significant.

When to Seek Emergency Care

---

References:
1. Camaschella C. “Hereditary Hemochromatosis.” New England Journal of Medicine. 2022;386:2099‑2110.
2. Gomaa A et al. “Risk of Hepatocellular Carcinoma in Patients With Hemochromatosis.” Hepatology. 2021;73(4):1231‑1240.
Additional guidance from Mayo Clinic, CDC, NIH National Institute of Diabetes and Digestive and Kidney Diseases, and the American Association for the Study of Liver Diseases.

```